Recombinant human tissue factor pathway inhibitor prevents thrombosis in a venous tuck model

Waleed H. Ezzat, John P. Dahl, Adam Luginbuhl, Eli Gordin, Howard Krein, Ryan N. Heffelfinger

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives/Hypothesis: Microvascular free tissue transfer has become a mainstay of reconstruction after resections for head and neck cancer. With current techniques, free flap failure is typically low; however, failure rates have been reported as high as 10%. Most thrombotic failures occur within the first few days postoperatively and tend to involve the venous anastomoses. We evaluated the efficacy of recombinant human tissue factor pathway inhibitor (rhTFPI), an anticoagulant that directly inhibits the extrinsic coagulation pathway, using a rat model of microvenous thrombosis. Study Design: Prospective, randomized. Methods: Sprague-Dawley rats were randomly assigned to either rhTFPI or saline groups. We performed a venous tuck procedure in the common femoral vein. Prior to closure, the anastamosis was irrigated with either rhTPFI (20 μg/mL) or normal saline. Survival of the anastomosis was measured via clinical assessment at regular postoperative intervals. After a postoperative period of 48 hours, sites were intraoperatively assessed and the vessels harvested. Results: There was a significant increase in vessel patency in rats treated topically with rhTFPI compared to controls receiving saline. There was no increase in bleeding complications in the treated group versus controls. Conclusions: Our data suggests that the use of topical rhTPFI increases venous anastomotic patency rates in vivo. The topical means of administration is attractive, as there seems to be a low percentage of systemic complications as is often seen with anticoagulation therapies. Future studies will investigate the potential efficacy in patients undergoing microvascular free tissue transfer.

Original languageEnglish (US)
Pages (from-to)2172-2176
Number of pages5
JournalLaryngoscope
Volume120
Issue number11
DOIs
StatePublished - Nov 1 2010

Fingerprint

Thrombosis
Topical Administration
Femoral Vein
Free Tissue Flaps
Head and Neck Neoplasms
Postoperative Period
Anticoagulants
Sprague Dawley Rats
Prospective Studies
Hemorrhage
Control Groups
Survival
lipoprotein-associated coagulation inhibitor
Therapeutics

Keywords

  • free flap
  • Microvascular
  • thrombosis
  • tissue factor pathway inhibitor
  • venous tuck

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Ezzat, W. H., Dahl, J. P., Luginbuhl, A., Gordin, E., Krein, H., & Heffelfinger, R. N. (2010). Recombinant human tissue factor pathway inhibitor prevents thrombosis in a venous tuck model. Laryngoscope, 120(11), 2172-2176. https://doi.org/10.1002/lary.20898

Recombinant human tissue factor pathway inhibitor prevents thrombosis in a venous tuck model. / Ezzat, Waleed H.; Dahl, John P.; Luginbuhl, Adam; Gordin, Eli; Krein, Howard; Heffelfinger, Ryan N.

In: Laryngoscope, Vol. 120, No. 11, 01.11.2010, p. 2172-2176.

Research output: Contribution to journalArticle

Ezzat, WH, Dahl, JP, Luginbuhl, A, Gordin, E, Krein, H & Heffelfinger, RN 2010, 'Recombinant human tissue factor pathway inhibitor prevents thrombosis in a venous tuck model', Laryngoscope, vol. 120, no. 11, pp. 2172-2176. https://doi.org/10.1002/lary.20898
Ezzat, Waleed H. ; Dahl, John P. ; Luginbuhl, Adam ; Gordin, Eli ; Krein, Howard ; Heffelfinger, Ryan N. / Recombinant human tissue factor pathway inhibitor prevents thrombosis in a venous tuck model. In: Laryngoscope. 2010 ; Vol. 120, No. 11. pp. 2172-2176.
@article{ac811ab51c734bc79019f8ce9539260a,
title = "Recombinant human tissue factor pathway inhibitor prevents thrombosis in a venous tuck model",
abstract = "Objectives/Hypothesis: Microvascular free tissue transfer has become a mainstay of reconstruction after resections for head and neck cancer. With current techniques, free flap failure is typically low; however, failure rates have been reported as high as 10{\%}. Most thrombotic failures occur within the first few days postoperatively and tend to involve the venous anastomoses. We evaluated the efficacy of recombinant human tissue factor pathway inhibitor (rhTFPI), an anticoagulant that directly inhibits the extrinsic coagulation pathway, using a rat model of microvenous thrombosis. Study Design: Prospective, randomized. Methods: Sprague-Dawley rats were randomly assigned to either rhTFPI or saline groups. We performed a venous tuck procedure in the common femoral vein. Prior to closure, the anastamosis was irrigated with either rhTPFI (20 μg/mL) or normal saline. Survival of the anastomosis was measured via clinical assessment at regular postoperative intervals. After a postoperative period of 48 hours, sites were intraoperatively assessed and the vessels harvested. Results: There was a significant increase in vessel patency in rats treated topically with rhTFPI compared to controls receiving saline. There was no increase in bleeding complications in the treated group versus controls. Conclusions: Our data suggests that the use of topical rhTPFI increases venous anastomotic patency rates in vivo. The topical means of administration is attractive, as there seems to be a low percentage of systemic complications as is often seen with anticoagulation therapies. Future studies will investigate the potential efficacy in patients undergoing microvascular free tissue transfer.",
keywords = "free flap, Microvascular, thrombosis, tissue factor pathway inhibitor, venous tuck",
author = "Ezzat, {Waleed H.} and Dahl, {John P.} and Adam Luginbuhl and Eli Gordin and Howard Krein and Heffelfinger, {Ryan N.}",
year = "2010",
month = "11",
day = "1",
doi = "10.1002/lary.20898",
language = "English (US)",
volume = "120",
pages = "2172--2176",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Recombinant human tissue factor pathway inhibitor prevents thrombosis in a venous tuck model

AU - Ezzat, Waleed H.

AU - Dahl, John P.

AU - Luginbuhl, Adam

AU - Gordin, Eli

AU - Krein, Howard

AU - Heffelfinger, Ryan N.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Objectives/Hypothesis: Microvascular free tissue transfer has become a mainstay of reconstruction after resections for head and neck cancer. With current techniques, free flap failure is typically low; however, failure rates have been reported as high as 10%. Most thrombotic failures occur within the first few days postoperatively and tend to involve the venous anastomoses. We evaluated the efficacy of recombinant human tissue factor pathway inhibitor (rhTFPI), an anticoagulant that directly inhibits the extrinsic coagulation pathway, using a rat model of microvenous thrombosis. Study Design: Prospective, randomized. Methods: Sprague-Dawley rats were randomly assigned to either rhTFPI or saline groups. We performed a venous tuck procedure in the common femoral vein. Prior to closure, the anastamosis was irrigated with either rhTPFI (20 μg/mL) or normal saline. Survival of the anastomosis was measured via clinical assessment at regular postoperative intervals. After a postoperative period of 48 hours, sites were intraoperatively assessed and the vessels harvested. Results: There was a significant increase in vessel patency in rats treated topically with rhTFPI compared to controls receiving saline. There was no increase in bleeding complications in the treated group versus controls. Conclusions: Our data suggests that the use of topical rhTPFI increases venous anastomotic patency rates in vivo. The topical means of administration is attractive, as there seems to be a low percentage of systemic complications as is often seen with anticoagulation therapies. Future studies will investigate the potential efficacy in patients undergoing microvascular free tissue transfer.

AB - Objectives/Hypothesis: Microvascular free tissue transfer has become a mainstay of reconstruction after resections for head and neck cancer. With current techniques, free flap failure is typically low; however, failure rates have been reported as high as 10%. Most thrombotic failures occur within the first few days postoperatively and tend to involve the venous anastomoses. We evaluated the efficacy of recombinant human tissue factor pathway inhibitor (rhTFPI), an anticoagulant that directly inhibits the extrinsic coagulation pathway, using a rat model of microvenous thrombosis. Study Design: Prospective, randomized. Methods: Sprague-Dawley rats were randomly assigned to either rhTFPI or saline groups. We performed a venous tuck procedure in the common femoral vein. Prior to closure, the anastamosis was irrigated with either rhTPFI (20 μg/mL) or normal saline. Survival of the anastomosis was measured via clinical assessment at regular postoperative intervals. After a postoperative period of 48 hours, sites were intraoperatively assessed and the vessels harvested. Results: There was a significant increase in vessel patency in rats treated topically with rhTFPI compared to controls receiving saline. There was no increase in bleeding complications in the treated group versus controls. Conclusions: Our data suggests that the use of topical rhTPFI increases venous anastomotic patency rates in vivo. The topical means of administration is attractive, as there seems to be a low percentage of systemic complications as is often seen with anticoagulation therapies. Future studies will investigate the potential efficacy in patients undergoing microvascular free tissue transfer.

KW - free flap

KW - Microvascular

KW - thrombosis

KW - tissue factor pathway inhibitor

KW - venous tuck

UR - http://www.scopus.com/inward/record.url?scp=78349303382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349303382&partnerID=8YFLogxK

U2 - 10.1002/lary.20898

DO - 10.1002/lary.20898

M3 - Article

C2 - 20939073

AN - SCOPUS:78349303382

VL - 120

SP - 2172

EP - 2176

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 11

ER -